Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy
Phase 3
Not yet recruiting
- Conditions
- Bietti Crystalline DystrophyInherited Retinal Diseases
- Interventions
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT06699108
- Locations
- 🇨🇳
Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, Shanghai, China
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Patients With Parkinson's Disease
- First Posted Date
- 2024-06-28
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT06480461
A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R09b in Severe AADC Deficiency
Phase 1
Not yet recruiting
- Conditions
- Aromatic L-amino Acid Decarboxylase Deficiency
- Interventions
- Genetic: VGN-R09b injection
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06432140
A Study to Evaluate the Tolerability, Safety and Efficacy of VGM-R02b
Phase 1
Recruiting
- Conditions
- Glutaric Aciduria Type IGlutaric Acidemia Type I
- Interventions
- Biological: VGM-R02b
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06217861
- Locations
- 🇨🇳
The Children's Hospital Zhejiang University Shcool of Medicine, Hangzhou, Zhejiang, China
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
Phase 1
Not yet recruiting
- Conditions
- Bietti Crystalline Dystrophy
- Interventions
- Genetic: VGR-R01
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05694598
- Locations
- 🇨🇳
Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, Shanghai, China
Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study
Not yet recruiting
- Conditions
- Hemophilia B
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05442528
A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients
Phase 1
Not yet recruiting
- Conditions
- Hemophilia B
- Interventions
- Genetic: VGB-R04
- First Posted Date
- 2022-07-01
- Last Posted Date
- 2022-07-01
- Lead Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05441553
- Locations
- 🇨🇳
Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath